Download Citation
Article Source:
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients
Polivkova V,
Rohon P,
Klamova H,
Cerna O,
Divoka M,
et al.
(2016)
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.
PLOS ONE 11(5): e0155959.
https://doi.org/10.1371/journal.pone.0155959